Motley Fool Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Motley Fool Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$299K	Sell	4,016 -25	-0.6%	-$1.75K	0.01%	226
2026 Q1	$300K	Buy	4,041 +638	+19%	+$46.2K	0.01%	215
2025 Q4	$260K	Buy	+3,403	New	+$223K	0.01%	220

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Motley Fool Asset Management's BBIO Position: Q2 2026 in Review

Motley Fool Asset Management reduced its BridgeBio Pharma (BBIO) stake by 0.62% in Q2 2026, selling an estimated $1.75K and leaving 4,016 shares worth $299K. The position accounts for 0.01% of the portfolio, ranked #226.

Motley Fool Asset Management first reported a position in BBIO in Q4 2025 and has held it in 3 quarters since. The position peaked at $300K in Q1 2026. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Motley Fool Asset Management held 4,016 shares of BridgeBio Pharma worth $299K as of Q2 2026.
Motley Fool Asset Management sold 25 BridgeBio Pharma shares in Q2 2026, an estimated $1.75K.
BridgeBio Pharma made up 0.01% of Motley Fool Asset Management's portfolio in Q2 2026, its #226 holding.
Motley Fool Asset Management first reported a position in BridgeBio Pharma in Q4 2025 and has held it in 3 quarters since.
Motley Fool Asset Management's BridgeBio Pharma position peaked at $300K in Q1 2026.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Motley Fool Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.